Lecanemab
- Generic Name
- Lecanemab
- Brand Names
- Leqembi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1260393-98-3
- Unique Ingredient Identifier
- 12PYH0FTU9
- Background
Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology of Alzheimer’s disease. Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain with high selectivity to Aβ protofibrils. In clini...
- Indication
Lecanemab is indicated for the treatment of Alzheimer’s disease. Treatment with lecanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
- Associated Conditions
- Alzheimer's Disease (AD)
- Associated Therapies
- -
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06602258
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Sharp Neurocognitive Research Center at Sharp Mesa Vista Hospital, San Diego, California, United States
🇺🇸University of California at San Francisco/UCSF, San Francisco, California, United States
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06530732
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 65
- Registration Number
- NCT06384573
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇦🇺Neuroscience Research Australia, Randwick, New South Wales, Australia
🇺🇸University of Alabama in Birmingham, Birmingham, Alabama, United States
Feasibility of Lecanemab Registry and Clinical Outcome Measures
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- HealthPartners Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06285448
- Locations
- 🇺🇸
HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States
Cognitive Neurology Unit Clinical Registry
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 500
- Registration Number
- NCT05925621
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05533801
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Ali Rezai
- Target Recruit Count
- 15
- Registration Number
- NCT05469009
- Locations
- 🇺🇸
West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 197
- Registration Number
- NCT05269394
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸USC Keck School of Medicine, Los Angeles, California, United States
🇨🇴Grupo de Neurociencias Sede de la Universidad de Antioquia, Medellín, Colombia
A Study of Subcutaneous Lecanemab in Healthy Participants
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05045716
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
- Conditions
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1400
- Registration Number
- NCT04468659
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.